Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID identifier: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies (2020)
- Journal of Theoretical Biology
(A1 Refereed original research article in a scientific journal) - Multiobjective optimization identifies cancer-selective combination therapies (2020)
- PLoS Computational Biology
(A1 Refereed original research article in a scientific journal) - Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1 (2020)
- Journal of Biological Chemistry
(A1 Refereed original research article in a scientific journal) - Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine (2020)
- Leukemia
(B1 Non-refereed article in a scientific journal) - RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses (2020)
- Leukemia
(A1 Refereed original research article in a scientific journal) - SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy (2020)
- PLoS Computational Biology
(A1 Refereed original research article in a scientific journal) - UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis (2020)
- Cancer Research
(A1 Refereed original research article in a scientific journal) - Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies (2019)
- Cell Chemical Biology
(A1 Refereed original research article in a scientific journal) - DNMT Inhibitors Increase Methylation in the Cancer Genome (2019)
- Frontiers in Pharmacology
(A1 Refereed original research article in a scientific journal) - Genome-wide off-targets of drugs: risks and opportunities (2019)
- Cell Biology and Toxicology
(B1 Non-refereed article in a scientific journal)



